Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw its shares climb 4.3% following the announcement of robust financial results for the fourth quarter and full-year 2025. The medical device company reported a significant 10.9% year-over-year increase in Q4 net sales, reaching $2.244 billion. Adjusted diluted earnings per share for the quarter stood at $2.42, exceeding expectations. This strong performance was primarily driven by higher procedure volumes and successful new product adoption. For the full fiscal year, Zimmer Biomet achieved total net sales of $8.232 billion, bolstered by a solid recovery in elective procedures and focused operational execution. The positive figures underscore the company's strong market position and effective strategy.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis